RxDoctor Payments Data

Sonia Rebeles, MD

Gynecology · Fresno, CANPI 1881891026

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Exeltis, USA Inc. at 57.0% of the total. Reporting peaked in 2024 at $11,151 and has fallen 96.0% since, to $446 in 2025. Among gynecology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,990in general payments, 2019–2025

Across 76 payments — averaging $210.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exeltis, USA Inc.$9K
  • Intuitive Surgical$5K
  • Coloplast$882
  • AbbVie$446
  • Covidien LP$45
  • Meditrina$42
  • plus $233 from 10 others

What the payments were for

  • Consulting fees$7,12545%
  • Speaking & faculty fees$1,87512%
  • Travel & lodging$4,33127%
  • Food & beverage$1,62210%
  • Education$1,0376%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,990 in reported general payments places this provider in the 90th percentile of 247 gynecology providers in California.

See all gynecology providers in California

Medicare billing

Part B allowed, 2024
$24,374
Medicare patients
90
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OsphenaOspemifene21$6,418
Estradiol48$2,546
Solifenacin Succinate11$1,020
Estradiol (Twice Weekly)Estradiol11$706
ProgesteroneProgesterone, Micronized15$588
Triamcinolone Acetonide12$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Duchesnay USA IncorporatedOsphena$16$6,41821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 247 gynecology providers in California.

Other gynecology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →